Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer

British Journal of Cancer

Volumn 73, Issue 12, 1996, Pages 1576-1580

  Gebbia, V ^a,b   Testa, A ^a   Gebbia, N ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b Institute of Pharmacology   (Italy)

Author keywords

Anorexia; Cachexia; Megestrol acetate; Progestin

Indexed keywords

ANTINEOPLASTIC AGENT; MEGESTROL ACETATE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; APPETITE; ARTICLE; BODY WEIGHT; CACHEXIA; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; FEMALE; GASTROINTESTINAL DISEASE; HEAD CANCER; HUMAN; KIDNEY CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NECK CANCER; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; STATISTICAL ANALYSIS; SURVIVAL; TREATMENT PLANNING; VEIN THROMBOSIS; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 0030057117     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.297     Document Type: Article

References (32)

1. ABRAMS JS, CIRRINCIONE C, AISNER J. BERRY D, HENDERSON IC, PANASCI L, ELLERTON J, MUSS H, KIRSHNER J, NOWAK B AND WOOD W. (1992). A phase III dose response trial of megestrol acetate (MA) in metastatic breast cancer (MBC). Proc. ASCO, 11, 56.
2. BECK SA AND TISDALE MJ. (1987). Production of lipolytic and proteolytic factors by a murine tumor producing cachexia in the host. Cancer Res., 47, 5919-5923.
3. BONETERRE J, BEAUCAIRE J, VENNIN P AND DEMAILLE A. (1988). Cancer cachexia. Adv. Clin. Oncol., 3, 391-405.
4. BRENNAN MF. (1981). Total parenteral nutrition in the cancer patient. N. Engl. J. Med. 305, 375-382.
5. BRENNAN MF AND BURT ME. (1981) Nitrogen metabolism in cancer patients. Cancer Treat. Rep., 65, 65 77.
6. BRUERA E, MACMILLAN K, KUEHN N, HANSON J AND MACDONALD N. (1990). A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer, 66, 1279-1282.
7. CREAGAN ET, INGLE JN, SCHUTT AJ AND SCHAID DJ. (1989). A prospective randomized controlled trial of megestrol acetate among high-risk patients with resected malignant melanoma. Am. J. Clin. Oncol., 12, 152-155.
8. DE WYS WD. (1979). Anorexia as a general effect of cancer. Cancer, 43, 2013-2019.
9. DE WYS WD. (1985). Management of cancer cachexia. Sem. Oncol., 12, 452-460.
10. FELIU J, GONZALES-BARON M, BERROCAL A, ARTAL A, ORDONEZ A, GARRIDO P, ZAMORA P, GARCIA DE PAREDES ML AND MONTERO JM. (1992). Usefulness of megestrol acetate in cancer cachexia and anorexia. A placebo controlled study. Am. J. Clin. Oncol., 15, 436-440.
11. HAMBURGER AW, PARNES H, GORDON GB, SHANTZ LM, O'DONNELL KA, COOPER MR AND AISNER J. (1988). Megestrol acetate-induced differentiation of 3T3-LI adipocytes in vitro. Sem. Oncol., 15, 76-78.
12. HECKMAYR M AND GATZMEIER U. (1992). Treatment of cancer weight loss in patients with advanced lung cancer. Oncology, 49 (suppl.2), 32-34.
13. KNOX LS, CROSBY LO, FEURER ID, BUZBY GP AND MILLER CL. ( 1983). Energy expenditure in malnourished cancer patients. Ann. Surg., 197, 152-162.
14. LOPRINZI CL, ELLISON NM, SCHAID DJ, KROOK DJ, ATHMANN LM, DOSE AM, MAILLIARD JA, JOHNSON TS, EBBERT LP AND GEERAERTS LH. (1990). Controlled trial of megestrol acetate for the treatment of the cancer anorexia and cachexia. J. Natl Cancer Inst., 82, 1127-1132.
15. LOPRINZI CL, JENSEN MD, NAI SJ AND SCHAID DJ. (1992). Effects of megestrol acetate on the pituitary-adrenal axis. Mayo Clin. Proc., 67, 1160-1162.
16. LOPRlNZI CL, SCHAID DJ, BURNHAM NL AND JENSEN MD. (1993). Body composition changes in patients who gain weight while receiving megestrol acetate. J. Clin. Oncol., 11, 152-154.
17. LOWRY SF AND MOLDAWER LL. (1990). Tumor necrosis factor and other cytokines in the pathogenesis of cancer cachexia. Prin. Practice Oncol., 4, 1-12.
18. MILLER AA, BECHER R AND SCHMIDT CG. (1988). Plasma concentrations of medroxyprogesterone acetate and megestrol acetate during long term follow-up in patients treated for metastatic breast cancer. J. Cancer Res. Clin. Oncol., 114, 186-190.
19. NIXON DW, HEYMFIELD SB, COHEN AE, KUTNER MH AND ANSLEY J. (1980). Protein-calorie undernutrition in hospitalized cancer patients. Am. J. Med., 68, 683-690.
20. PARNES HL AND AISNER J. (1992). Protein calorie malnutrition and cancer therapy. Drug Safety, 7, 404-416.
21. PARNES H, CONAWAY M, KORNBLITH MR, COOPER MR, KIRSHNER J, DAVILA E, SILVER R, AISNER J, MORTIMER J, OZER H AND VINCIGUERRA V. (1994). A dose response trial of megestrol acetate (MA) for the treatment of cachexia in patients with advanced cancer. Proc. ASCO, 13, 451.
22. SCHMOLL E. (1992). Risks and benefits of various therapies for cancer anorexia. Oncology, 49 (suppl.2), 43-45.
23. SEDLACEK SM. (1988). An overview of megestrol acetate for the treatment of advanced breast cancer. J. Clin. Oncol., 15 (suppl. 2), 3-13.
24. SPLINTER TAW. (1992). Cachexia in cancer: a clinicians' view. Ann. Oncol., 3 (suppl.3), 25-27.
25. TATTERSALL MNH, SIMES RJ, LUMLEY T, BELLER E, LEVI J AND DALLEY D. (1994). Improved quality of life (QOL) with megestrol acetate (MA) for patients with advanced non-endocrine sensitive cancer: a placebo-controlled randomized trial. Proc. ASCO, 13, 435.
26. TCHEKMEDYIAN NS, TAIT N AND AISNER J. (1986). High dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer. Semin. Oncol., 13, 20-25.
27. TCHEKMEDYIAN NS, HICKMAN M, SIAU J, GRECO FA, KELLER J, BROWDER H, AND AISNER J. (1992a). Megestrol acetate in cancer anorexia and weight loss. Cancer, 69, 1269-1274.
28. TCHEKMEDYIAN NS, ZAHYNA D, HALPERT C AND HEBER D. (1992b). Clinical aspects of nutrition in advanced cancer. Oncology, 49 (suppl.2), 3-7.
29. TERNELL M, MOLDAWER LC AND LONROTH C. (1987). Plasma protein synthesis in experimental cancer compared to paraneoplastic condition, including monokine administration. Cancer Rex., 47, 5825-5830.
30. TISDALE MJ. (1993). Cancer cachexia. Anticancer Drugs, 4, 115 125.
31. YOUNG WR, (1977). Energy metabolism and requirements in the cancer patients. Cancer Res., 37, 2336-2347.
32. WILLEMSE PHB, VAN DERPLOEG E, SLEIJFER DTH, TJABBES T AND VANVEELEN H. (1990). A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur. J. Cancer, 26, 337 343.